GHR and hepatocellular carcinoma: We show that a circulating GHRA successfully and significantly improves cisplatin (in melanoma) or sorafenib (in HCC) effects and acts as a springboard for future investigations directed at assessing treatments with approved GHR antagonists and anti-cancer drugs for GHR-expressing human cancers.